Truist downgraded Longboard Pharmaceuticals to Hold from Buy with a $60 price target The firm said the downgrade comes after the announcement of Longboard’s acquisition by Lundbeck. Truist doesn’t expect another suitor to emerge and notes that Lundbeck CEO Charl van Zyl was at UCB from 2017 to 2023, who was likely involved in tthe diligence of fintepia. The firm believes this is a good outcome for all parties involved.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LBPH:
- Longboard Pharmaceuticals downgraded to Hold from Buy at Truist
- Longboard Pharmaceuticals downgraded to Neutral from Outperform at Baird
- M&A News: Lundbeck to Acquire Longboard (NASDAQ:LBPH) for $2.6B
- Boeing to cut 10% of workforce, Lundbeck to acquire Longboard: Morning Buzz
- Longboard Pharmaceuticals downgraded to Neutral from Outperform at Wedbush